SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-23-008597
Filing Date
2023-07-24
Accepted
2023-07-24 16:20:07
Documents
15
Period of Report
2023-07-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_071923.htm   iXBRL 8-K 31483
2 PURCHASE AND SALE AGREEMENT ex10-1.htm EX-10.1 117383
3 SALES AGREEMENT ex10-2.htm EX-10.2 11587
7 GRAPHIC image_001.jpg GRAPHIC 9299
  Complete submission text file 0001387131-23-008597.txt   375834

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE admp-20230719.xsd EX-101.SCH 3054
5 XBRL LABEL FILE admp-20230719_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE admp-20230719_pre.xml EX-101.PRE 22385
9 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_071923_htm.xml XML 3301
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 231105246
SIC: 2834 Pharmaceutical Preparations